Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development (PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 showing encouraging results in Alzheimer’s disease). Pharnext has also developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY™.

Funding: Looking for a non deal roadshow